Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 16/20 | 0.60 |
| ▸ | TACR3 | P29371 | 15/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.59 |
| ▸ | TRPV4 | Q9HBA0 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5446918 | 0.91 | TACR2 (0.71) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5455843 | 0.91 | TACR2 (0.57) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5937385 | 0.88 | TACR2 (0.56) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5442075 | 0.87 | TACR2 (0.69) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5445925 | 0.86 | TACR2 (0.80) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5937443 | 0.86 | TACR2 (0.54) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5908809 | 0.86 | TACR2 (0.69) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5447099 | 0.85 | DHODH (0.51) | TACR2TACR3 | |
| SCHEMBL5908720 | 0.85 | TACR2 (0.72) | TACR2TACR3OPRM1TRPV4 | |
| SCHEMBL5436339 | 0.84 | TACR2 (0.71) | TACR2TACR3OPRM1TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | KCNQ3, KCNK3, KCNK2 | TACR2 22/4885TACR3 45/4885OPRM1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.